Jianmin Pharmaceutical GroupLtd Management

Management criteria checks 3/4

Jianmin Pharmaceutical GroupLtd's CEO is Jun Wang, appointed in Sep 2022, has a tenure of 2.17 years. directly owns 0.23% of the company’s shares, worth CN¥14.76M. The average tenure of the management team and the board of directors is 2.2 years and 2.2 years respectively.

Key information

Jun Wang

Chief executive officer

CN¥891.4k

Total compensation

CEO salary percentage	n/a
CEO tenure	2.2yrs
CEO ownership	0.2%
Management average tenure	2.2yrs
Board average tenure	2.2yrs

Recent management updates

Recent updates

CEO

Jun Wang (47 yo)

2.2yrs

Tenure

CN¥891,400

Compensation

Mr. Jun Wang was Vice President of KPC Pharmaceuticals,Inc until September 08, 2020. He is Managing Director of Jianmin Pharmaceutical Group Co.,Ltd. He is Director and President of Jianmin Pharmaceutical...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jun Wang	President	2.2yrs	CN¥891.40k	0.23% CN¥ 14.8m
Chaoyang Cheng	Financial Director	2.2yrs	CN¥511.20k	0.055% CN¥ 3.6m
Zhenbo Hu	VP & Director	1.3yrs	CN¥210.40k	no data
Jie Zhou	Secretary	2.2yrs	CN¥408.80k	0.024% CN¥ 1.6m
Xuejun Pei	Vice President	2.2yrs	CN¥540.00k	0.12% CN¥ 7.8m
Zhijun Huang	Vice President	2.2yrs	CN¥540.00k	0.11% CN¥ 6.9m

2.2yrs

Average Tenure

49yo

Average Age

Experienced Management: 600976's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jun Wang	President	2.2yrs	CN¥891.40k	0.23% CN¥ 14.8m
Zhenbo Hu	VP & Director	1.3yrs	CN¥210.40k	no data
Qin He	Chairman	2.2yrs	CN¥2.10m	0.27% CN¥ 17.5m
Qijing Xiao	Chairman of the Supervisory Board	2.2yrs	no data	no data
Yunpei Guo	Independent Director	2.2yrs	CN¥90.00k	no data
Rong Pei	Director	2.2yrs	CN¥60.00k	no data
Liang Xu	Director	2.2yrs	CN¥60.00k	no data
Shuqu Li	Independent Director	2.2yrs	CN¥90.00k	no data
Hu Jian	Supervisor	2.2yrs	no data	no data
Li Chen	Supervisor	2.2yrs	no data	no data
Jingqiu Tang	Supervisor	2.2yrs	no data	no data
Zhi Yang	Independent Director	2.2yrs	CN¥90.00k	no data

2.2yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 600976's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Jianmin Pharmaceutical GroupLtd Management

Management criteria checks 3/4

Key information

Recent management updates

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

No independent directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.54 (vs CN¥1.07 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 24%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.65 in 1Q 2023)

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings released: EPS: CN¥3.41 (vs CN¥2.68 in FY 2022)

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

Investor sentiment deteriorates as stock falls 16%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 16, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Full year 2022 earnings released: EPS: CN¥2.68 (vs CN¥2.13 in FY 2021)

Investor sentiment improves as stock rises 16%

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.59 in 3Q 2021)

Investor sentiment improved over the past week

Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.

Second quarter 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.64 in 2Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.45 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.25 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.60 in FY 2019)

Jianmin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥24.68

Third quarter earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day high - CN¥23.96

First half earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 13, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age